To evaluate the accuracy and reasoning capabilities of large multimodal language models compared with those of neuroradiology subspecialty-trained radiologists in neuroradiology case interpretation. This experimental study used custom-made 401 radiologic quizzes derived from articles published in RadioGraphics covering neuroradiology and head and neck topics (October 2020 to February 2024). We prompted the GPT-4 Turbo with Vision (GPT-4V), GPT-4 Omni, Gemini Flash, and Claude models to provide the top three differential diagnoses with a rationale and describe examination characteristics such as imaging modality, sequence, use of contrast, image plane, and body part. The temperature was adjusted to 0 and 1 (T1). Two neuroradiologists answered the same questions. The accuracies of the large language models (LLMs) and the neuroradiologists were compared using generalized estimating equations. Three neuroradiologists assessed the rationale provided by the LLMs for their differential diagnoses using four-point scales, separately for specific lesion locations and imaging findings, and evaluated the presence of hallucinations and the overall acceptability of the responses. Top-3 accuracy (i.e., correct answers present among top-3 differential diagnoses) of LLMs ranged from 29.9% (120 of 401) to 49.4% (198 of 401, obtained with GPT-4V in the T1 setting), while radiologists achieved 80.3% (322 of 401) and 68.3% (274 of 401), respectively (P < 0.001). Regarding the rationale for differential diagnoses, GPT-4V (T1) accurately identified both the specific lesion location and imaging findings in 30.7% (123 of 401) and 12.9% (16 of 124) of cases without textual clinical history. Hallucinations occurred in 4.5% (18 of 401), and only 29.4% (118 of 401) of the LLM-generated analyses were deemed acceptable. GPT-4V (T1) demonstrated high accuracy in identifying the imaging modality (97.4% [800 of 821]) and scanned body parts (92.2% [756 of 820]). LLMs remarkably underperformed compared with neuroradiologists and showed unsatisfactory reasoning for their differential diagnoses, with performance declining further in cases without textual input of clinical history. These findings highlight the limitations of current multimodal LLMs in neuroradiological interpretation and their reliance on text input.
To evaluate the diagnostic performance of the "probable hepatocellular carcinoma (HCC)" category in the Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) v2022 guidelines. This multicenter retrospective study included patients at risk of HCC who underwent gadoxetic acid-enhanced MRI between January 2015 and June 2018; a subgroup of these patients also underwent liver CT. Eligible patients had at least one non-cystic lesion (≥10 mm) with a reference standard. Four radiologists interpreted the images independently and the results were pooled. The performance of "definite HCC" and "probable HCC" together and "probable HCC" alone were compared between v2018 and v2022. A total of 2,237 patients (1,666 men; mean age, 59 ± 11 years) with 2,445 lesions were included. In v2022, 1.5% (143/9,780) of the lesions were additionally categorized as "probable HCC" by four reviewers on MRI; among these, 104 lesions were not HCCs. Focal nodular hyperplasia (FNH) or FNH-like nodules constituted 90.4% (94/104) of the false positives. When "definite HCC" and "probable HCC" were combined, v2022 showed higher sensitivity (83.7% [5,670/6,776] vs. 83.1% [5,631/6,776]) but lower specificity (77.1% [2,316/3,004] vs. 80.6% [2,420/3,004]) than v2018 (P < 0.001). For "probable HCC" alone, v2022 showed a lower positive predictive value (PPV) than v2018 (64.1% [373/582] vs. 76.1% [334/439], P < 0.001). In v2022, lesions with non-rim arterial-phase hyperenhancement (APHE) showed a lower PPV than those without APHE (42.3% [91/215] vs. 76.8% [282/367], P < 0.001). In the CT subgroup (n = 1,590), 1.6% (99/6,360) of the lesions were reassessed as "probable HCC," and its PPV was 83.8% (83/99) in v2022 whereas no lesions were classified as "probable HCC" under v2018. The revised "probable HCC" category in the KLCA-NCC v2022 aligns with updates in the diagnostic flow, demonstrating acceptable performance on MRI and CT. Notably, FNH or FNH-like nodules can be misclassified as "probable HCC" when MRI is used.
Coronavirus disease 2019 (COVID-19) vaccine-related myocarditis (C-VRM) is a potential adverse event following mRNA-based vaccination. Cardiac magnetic resonance imaging (CMR) is pivotal for diagnosing and monitoring myocarditis. This study compared quantitative CMR findings among C-VRM, COVID-19 myocarditis, and other myocarditis in the Korean population, and identified prognostic factors associated with adverse outcomes. This retrospective multicenter study included patients diagnosed with various types of myocarditis who underwent CMR in four tertiary-care hospitals between October 2018 and January 2023. Clinical data and CMR findings, including cine, native T1, T2, extracellular volume (ECV), and late gadolinium enhancement (LGE) were analyzed. Differences in CMR parameters among myocarditis types were analyzed using linear regression. Predictors of adverse outcomes, defined as a composite of left ventricular ejection fraction (LVEF) of < 40% at follow-up and all-cause mortality, were assessed using logistic regression analysis. A total of 82 patients (mean age, 42.8 ± 19.2 years; 40 men) were included: 29 with C-VRM, 7 with COVID-19 myocarditis, and 46 with other myocarditis. C-VRM showed significantly lower native T1, T2, and ECV than other myocarditis (P = 0.001, 0.022, and 0.001, respectively), after adjustment for age, sex, and time from symptom onset to CMR. Among the 74 patients with follow-up LVEF data, seven (9.5%) experienced adverse outcomes. Maximum ECV z-score (odds ratio [OR], 1.457; 95% confidence interval [CI], 1.062-1.998; P = 0.020) and LGE extent (OR, 1.109; 95% CI, 1.029-1.194; P = 0.007) remained independent predictors after adjusting for age and initial LVEF, while myocarditis type was not associated with prognosis. In this Korean multicenter cohort, CMR markers of myocardial injury were lower in C-VRM than in other myocarditis types, whereas prognosis was more strongly associated with injury severity than with disease subtype.
暂无摘要（点击查看详情）
Although pediatric thyroid cancer is rare, it has characteristics distinct from those of adult thyroid cancer. Thyroid nodules in children present a higher risk of malignancy, more frequent lymph node and distant metastases, and distinct molecular profiles compared to adults. Despite a more aggressive initial presentation, the long-term prognosis for children is excellent, with paradoxically low mortality rates, even in patients with distant metastases. Therefore, it is questionable whether ultrasound-based risk-stratification systems primarily developed for adults can be directly applied to children. The 2021 Korean Thyroid Imaging Reporting and Data System (K-TIRADS) introduced pediatric-specific biopsy cut-offs and risk-adapted considerations, improving sensitivity, specificity, and overall accuracy. Nevertheless, challenges remain in achieving better diagnostic performance. Specific considerations must also be noted when evaluating pediatric thyroid nodules, such as the diffuse sclerosing subtype of papillary thyroid cancer and intrathyroidal ectopic thymus. Overdiagnosis and age-related heterogeneity further complicate risk assessment and management. Future guidelines could adopt stratified approaches based on patient age and sonographic mimickers, with additional integration of molecular profiling and artificial intelligence-assisted decision support. This review summarizes the current state of ultrasonographic evaluation of pediatric thyroid nodules, including the 2021 K-TIRADS, and discusses future refinements for pediatric-specific ultrasound risk-stratification systems.
To evaluate the impact of adding CT to ultrasound (US) for nodal assessment in patients with papillary thyroid microcarcinoma (PTMC), particularly in those with US-node-negative disease. This single-center retrospective study included consecutive patients with PTMC (≤1 cm on US) who underwent both US and CT for PTMC staging between August 2016 and January 2020, and subsequently underwent surgery including neck dissection. The number of patients with clinical N1 and pathological N1 disease was assessed. The diagnostic performance of US, CT, and combined US + CT (positive if either was positive) for macroscopic lymph node metastasis (LNM) (i.e., metastatic tumor foci >2 mm) was evaluated. Cases with discordant nodal staging between US and CT were identified. The diagnostic utility of CT was also assessed in a subgroup of patients with node-negative findings on US. Among 982 patients (mean age ± standard deviation, 47.3 ± 11.5 years; 774 female), pathological analysis confirmed cervical LNM in 377 patients, including macroscopic, microscopic, and size-unknown LNM in 187, 175, and 15 patients, respectively. The addition of CT to US improved sensitivity for detecting macroscopic LNM compared to US alone (68.4% [128/187] vs. 26.7% [50/187]; P < 0.001), while maintaining high specificity despite a significant decrease (90.9% [709/780] vs. 97.2% [758/780]; P < 0.001). Discordant nodal staging between US and CT regarding macroscopic LNM was observed in 149 cases (15.2% [149/982]), with 131 patients (87.9% [131/149]) being upstaged by CT. In patients with node-negative US findings, CT detected US-undetected macroscopic LNM in 78 patients (8.7% [78/895]) and exhibited a sensitivity of 56.9% (78/137) and specificity of 93.5% (709/758) for macroscopic LNM. The integration of CT with US improved sensitivity for detecting macroscopic LNM in patients with PTMC, identifying those who would otherwise be inappropriately considered candidates for active surveillance based solely on US findings. This may assist in refining patient management.
Purpose To investigate the prognostic interaction between emphysema and interstitial lung abnormalities (ILAs) in relation to mortality among individuals undergoing lung cancer screening (LCS). Materials and Methods This retrospective cohort study included individuals screened in the Korean National Lung Cancer Screening Program between August 2019 and December 2020. Emphysema and ILAs were identified from CT study reports found in the program records. The primary study outcomes were mortality after a lung cancer diagnosis and mortality without a lung cancer diagnosis, analyzed using Fine-Gray subdistribution hazard models. Results Among 124 121 LCS participants (mean age, 61.6 years ± 5.3; 121 876 male), 13.8% (17 082) and 2.6% (3275) had emphysema and ILAs, respectively, with ILAs present in 7.0% (1200 of 17 082) of those with emphysema. The association between emphysema and mortality after a lung cancer diagnosis differed based on ILA status (P for interaction = .003). Emphysema was associated with increased mortality only in the absence of ILAs (adjusted subdistribution hazard ratio [sHR], 2.32; 95% CI: 1.97, 2.73; P < .001). In contrast, ILAs were associated with elevated mortality regardless of emphysema status, although the association was attenuated in the presence of emphysema (adjusted sHR without emphysema, 5.29 [95% CI: 4.12, 6.78]; with emphysema, 3.04 [95% CI: 2.32, 3.96]; both P < .001). The combined presence of ILAs and emphysema conferred the highest mortality risk (adjusted sHR: 7.04; 95% CI: 5.42, 9.15), albeit not significantly higher than ILAs alone (P = .09), suggesting that ILAs drive the increased risk when the conditions coexist. Similar patterns were observed for mortality without a preceding lung cancer diagnosis. Conclusion ILAs diminished the prognostic significance of emphysema and were the primary driver of mortality risk when both conditions were present. Keywords: Lung Cancer Screening, Low-Dose CT, Interstitial Lung Abnormalities, Interstitial Lung Diseases, Emphysema Supplemental material is available for this article. © RSNA, 2026.
This study aimed to evaluate the prognostic value of [¹⁸F]ALF-NOTA-FAPI-04 PET/CT-derived parameters, including the maximum standardized uptake value (SUVmax), FAPI-avid tumor volume (FTV), and total lesion FAP expression (TLF), in patients with recurrent gastric cancer undergoing combined chemoimmunotherapy. We sought to establish a noninvasive imaging biomarker framework to optimize patient stratification and therapeutic decision-making. This retrospective cohort study analyzed 51 patients with recurrent gastric cancer who received programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy after gastrectomy. All patients underwent [¹⁸F]ALF-NOTA-FAPI-04 PET/CT within 14 days of chemoimmunotherapy. Semi-quantitative parameters (SUVmax, FTV, and TLF) were derived using semi-automated tumor segmentation. The primary endpoint of this study was the assessment of the clinical efficacy of chemoimmunotherapy, categorized as a durable or nondurable clinical benefit. The secondary endpoints included progression-free survival (PFS) and overall survival (OS). In a subgroup of 16 patients who underwent sequential [¹⁸F]FDG PET/CT within seven days of [¹⁸F]ALF-NOTA-FAPI-04 PET/CT, tracer uptake values were compared between the two PET/CT examinations. 51 patients were included. The median PFS and OS were 7 and 10 months, respectively. Durable clinical benefit (DCB) was observed in 30 patients and showed significantly lower SUVmax, FTV, and TLF values than non-DCB. TLF demonstrated the highest diagnostic accuracy for DCB (area under the receiver operating characteristic curve [AUC] = 0.80). Multivariable analysis identified TLF ≥ 188.88 SUVbw·cm³ as an independent factor associated with PFS (hazard ratio [HR] = 7.29, P = 0.001) and FTV ≥ 44.17 cm³ as an independent factor associated with OS (HR = 5.16, P = 0.010). In the subgroup analysis of 16 patients, semi-quantitative analysis demonstrated consistently higher values of [¹⁸F]ALF-NOTA-FAPI-04-derived parameters than [¹⁸F]FDG-derived parameters (all P < 0.001). [¹⁸F]ALF-NOTA-FAPI-04 PET/CT may be a useful imaging tool for predicting clinical outcomes in patients with recurrent gastric cancer undergoing treatment with PD-1 inhibitors and chemotherapy.
Clinical utility and dynamics of plasma biomarkers in early-onset dementia remain underexplored. To investigate plasma biomarker trajectories and their associations with clinical outcomes in early-onset Alzheimer disease (EOAD) and frontotemporal dementia (FTD). This multicenter, prospective cohort study analyzed participants in phase 1 of the Longitudinal Study of Early-onset Dementia and Family Members (LEAF), which was conducted from April 2021 through December 2023 in 34 centers across South Korea. Patients with β-amyloid-positive EOAD and FTD were included and underwent annual blood sampling and clinical assessment, within a follow-up period of approximately 2 years. Data were analyzed between June 2025 and March 2026. Levels of plasma phosphorylated tau 217 (p-tau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL) biomarkers were analyzed using assays. (1) Associations of baseline biomarkers with clinical outcomes (assessed with the Mini-Mental State Examination [MMSE] and the Clinical Dementia Rating-Sum of Boxes [CDR-SB] for the EOAD group, or the frontotemporal lobar degeneration [FTLD]-modified CDR-SB for the FTD group), (2) biomarker trajectories, and (3) association of biomarker level changes and clinical outcomes. A total of 322 participants with p-tau217, GFAP, and NfL analyses were stratified into the EOAD or FTD group based on their diagnosis. The EOAD group (n = 245) had a mean (SD) age of 61.8 (5.4) years and included 163 females (66.5%), while the FTD group (n = 77) had a mean (SD) age of 65.1 (7.3) years and included 45 females (62.3%). In the EOAD group, higher log2-transformed baseline p-tau217, GFAP, and NfL were each associated with faster decline in the MMSE score (association estimate [SE], -0.390 [0.127], P = .002; -0.775 [0.164], P < .001; and -0.679 [0.182], P < .001, respectively) and the CDR-SB score (estimate [SE], 0.401 [0.099], P < .001; 0.535 [0.126], P < .001; and 0.693 [0.122], P < .001, respectively). In the FTD group, GFAP and NfL were associated with MMSE decline (estimate [SE], -2.118 [0.566], P < .001 and -2.360 [0.428], P < .001, respectively), whereas p-tau217 was not (estimate [SE], 0.071 [0.418], P = .87). No biomarker was associated with FTLD-modified CDR-SB score change. Longitudinally, all mean (SD) biomarker levels increased in the EOAD group (p-tau217: 0.253 [0.077] pg/mL, P = .001; GFAP: 0.173 [0.040] pg/mL, P < .001; NfL: 0.149 [0.045] pg/mL, P = .001), whereas in the FTD group, only NfL level showed an upward pattern (0.251 [0.127] pg/mL, P = .05). Annualized biomarker changes were associated with worsening clinical outcomes in the EOAD group, but not in the FTD group. GFAP and NfL level increases were associated with MMSE score decline (estimate [SE], -0.005 [0.002], P = .007 and -0.010 [0.003], P = .001, respectively), while p-tau217 level increases were associated with CDR-SB score worsening (estimate [SE], 0.072 [0.024], P = .003) in the EOAD group. In this cohort study of patients with EOAD and FTD, baseline p-tau217, GFAP, and NfL were consistently associated with clinical outcomes in the EOAD group, whereas GFAP and NfL were associated with cognition only in the FTD group. These findings demonstrate distinct characteristics of plasma biomarkers in EOAD and FTD, supporting their potential utility for risk stratification.
To evaluate the diagnostic potential of fluid suppression (FS) techniques combined with amide proton transfer-weighted imaging (APTw) for assessment of isocitrate dehydrogenase (IDH) mutation status, glioma subtypes, and tumor proliferation. This retrospective study included 117 patients with adult-type diffuse gliomas. Conventional APTw, FS-APTw, and spillover-corrected FS-APTw (SCFS-APTw) metrics were calculated from 3T MRI data in tumor parenchyma, necrotic or cystic regions, and contralateral normal-appearing white matter. APTw signals were compared across the three techniques within each region, between IDH-mutant and IDH-wildtype gliomas, and among astrocytoma, oligodendroglioma, and glioblastoma subtypes. Diagnostic performance for distinguishing IDH mutation status and glioma subtypes was assessed using receiver operating characteristic (ROC) analysis. Correlations between APTw metrics and Ki-67 expression were also analyzed. Both FS-APTw and SCFS-APTw significantly reduced signal intensity in tumor parenchyma and necrotic or cystic regions, with SCFS-APTw demonstrating a stronger suppression effect. IDH-wildtype gliomas showed significantly higher APTw metrics than IDH-mutant gliomas (all P < 0.001). Glioblastomas exhibited significantly higher metrics than oligodendrogliomas (all corrected P ≤ 0.015) and astrocytomas (all corrected P < 0.001). SCFS-APTw achieved the highest area under the ROC curve (AUC) of 0.846 for identification of IDH mutation status. For differentiation between astrocytomas and glioblastomas, the 90th percentile of APTw yielded the highest AUC (0.860), followed by SCFS-APTw (0.849). For discrimination between oligodendrogliomas and glioblastomas, the highest AUC (0.832) was obtained using the 90th percentile of SCFS-APTw. None of these metrics successfully differentiated oligodendrogliomas from astrocytomas. SCFS-APTw demonstrated the strongest correlation with Ki-67 expression (r = 0.451). FS techniques effectively reduce elevated APTw signals originating from fluid compartments. Their combination with APTw imaging enables evaluation of IDH mutation status, glioma subtypes, and tumor proliferative activity in adult-type diffuse gliomas.
Accurate and equitable prediction of trauma-related in-hospital mortality is critical for guiding clinical decisions and optimising trauma care resources. Traditional severity scoring systems like the Injury Severity Score (ISS) do not account for demographic factors, potentially limiting their fairness and generalisability across diverse populations. We developed and externally validated an artificial intelligence (AI) model based on ISS and integrated demographic features (age and sex) to predict in-hospital mortality after trauma. Data from the Korean Trauma Data Bank were used for model development and internal validation, comprising 121,418 patients with trauma aged ≥15 years treated at 19 trauma centres in South Korea (2017-2022). External validation was performed on an independent cohort of 7458 patients from five trauma centres (four in South Korea and one in Australia, 2022-2024). The primary outcome was trauma-related in-hospital mortality. Predictive performance was assessed using area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, accuracy, and balanced accuracy. Fairness was evaluated by comparing AUROC differences across age (<65 vs ≥65 years) and sex (female vs male) subgroups. The ISS-based AI model incorporating age and sex achieved high predictive performance (internal validation AUROC, 0.934; external validation AUROC range, 0.901-0.920), outperforming conventional ISS-based methods. The model also demonstrated improved fairness, showing reduced AUROC differences across subgroups (age: 0.068 vs 0.091; sex: 0.021 vs 0.046 for AI model vs ISS, respectively). Scaling an ISS-based AI model through demographic integration yielded accurate, fair, and generalisable predictions of trauma-related in-hospital mortality. This approach may enhance trauma care decision-making and enable more equitable resource allocation across diverse clinical settings. This research was supported by the MSIT (Ministry of Science and ICT), Korea, under the ITRC (Information Technology Research Center) support program (IITP-2025-RS-2024-00438239) and the Institute of Information & Communications Technology Planning & Evaluation (IITP) grant funded by the Korea government (MSIT) (RS-2024-00509257, Global AI Frontier Lab). In addition, this research was supported by the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (RS-2025-02220492).
This study aims to evaluate the global burden of adverse effects of medical treatment (AEMT) using data from the Global Burden of Disease Study (GBD) 2021. Data were extracted from the GBD 2021, covering 204 countries/territories from 1990 to 2021. AEMT was defined using ICD-9 and ICD-10 codes, encompassing complications from medical procedures, treatments, or healthcare exposures. Estimates were categorized into fatal and non-fatal outcomes and stratified by age, sex, year, and covariates, including the Socio-demographic Index (SDI). Mortality-incidence ratios (MIRs), defined as the ratio of mortality calculated by dividing the number of deaths by the total incident cases, were analyzed. In 2021, the global age-standardized prevalence, incidence, disability-adjusted life years (DALYs), and mortality rates of AEMT were 11.48 (95% uncertainty interval [UI], 8.86-14.13), 150.44 (131.19-171.81), 64.19 (51.06-73.11), and 1.53 (1.29-1.68) per 100,000 population, respectively. DALY rates were highest in the early neonatal group (4,789.47 per 100,000 population [95% UI, 3,682.00-5,963.30]), while mortality rates followed a U-shaped pattern across age groups. In 2021, MIRs were highest at both ends of the age range: the early neonatal group (0.58 [95% UI, 0.55-0.58]) and the 95+ age group (0.05 [0.04-0.06]). This pattern was consistent across all SDI quintiles, with higher MIRs observed in lower SDI quintiles. The significantly higher prevalence and incidence rates of AEMT among the older population in high SDI quintiles, compared to lower SDI quintiles, could be attributed to the healthcare overutilization, highlighting the need for policy adjustments.
To evaluate the feasibility of streamlined radioembolization using yttrium-90 resin microspheres without lung shunt fraction (LSF) assessment in patients with intrahepatic cholangiocarcinoma (ICC). This single-center retrospective study included 23 patients with ICC who underwent radioembolization using resin microspheres (SIR-Spheres; SIRTEX, Woburn, MA, USA) without LSF measurement between April 2022 and April 2025. Eligibility criteria, based on prior institutional data, included a target tumor size less than 10 cm, absence of hepatic vein invasion and intratumoral dysmorphic vessels, and an institutional waiting time exceeding one week for macroaggregated albumin scintigraphy. All patients had at least one follow-up imaging study. Radiation activity was prescribed according to tumor location, liver function, and clinical setting, using both single-compartment and multi-compartment dosimetry under the assumptions of a 5% LSF and a tumor-to-normal (TN) ratio of 3. Post-treatment yttrium-90 PET/CT dosimetry was performed in 12 patients. Treatment-related toxicity, tumor response, and local tumor progression-free survival were analyzed. The median administered activity was 1.43 GBq (interquartile range, 0.89-2.15). The median mean absorbed dose to the perfused tissue was 147 Gy, and the median tumor absorbed dose (TAD) was 339 Gy, assuming a TN ratio of 3. Post-treatment PET/CT analysis demonstrated a median TAD of 371 Gy and a median TN ratio of 4.7. No patient developed symptomatic radiation pneumonitis. Best tumor response was partial response in 52% of patients and stable disease in 48%. Local tumor progression-free survival rates at six months, one year, and two years were 95.2%, 81.1%, and 81.1%, respectively. Streamlined radioembolization without LSF assessment appears feasible and may represent a practical alternative to conventional multi-step workflows in patients with ICC measuring less than 10 cm.
Spontaneous intracranial hypotension is a neurologic condition that is caused by a spinal cerebrospinal fluid (CSF) leak. The resulting CSF hypovolemia can manifest as a variety of clinical symptoms, with orthostatic headache being the most common. Although this disease has been recognized for decades, modern understanding of the types of causative spinal CSF leaks, diagnostic imaging tests to localize these leaks, and treatment options has evolved substantially in recent years. In this focused review article, we will provide an overview of the current diagnosis and treatment of spontaneous intracranial hypotension. We will emphasize recent improvements in understanding the pathophysiology of spinal leaks, developments in myelographic techniques to localize CSF leaks, and new treatment options for each type of leak.
This study aimed to assess the association between exposure to gadolinium-based contrast agents (GBCAs) and the risk of parkinsonism according to the GBCA type. Individuals aged ≥40 years who underwent first-ever magnetic resonance imaging (MRI) examinations between 2011 and 2014 were identified from the Korean nationwide population-based health insurance claims database and followed up until 2022. Individuals were divided into those who underwent at least one GBCA-enhanced MRI, and those who underwent only non-enhanced MRI. GBCA-exposed individuals were further categorized into those exposed only to linear or macrocyclic GBCAs, after excluding those exposed to both types. The primary event of interest was all-cause parkinsonism. Secondary events included all-cause parkinsonism requiring medication, Parkinson's disease (PD), atypical parkinsonism, and secondary parkinsonism. Hazard ratios (HRs) were estimated using multivariable Cox proportional hazard regression models for exposure to linear and macrocyclic GBCAs, with the non-enhanced MRI group serving as a reference. The models were adjusted for age, sex, smoking status, alcohol consumption, regular exercise, body mass index, estimated glomerular filtration rate, and comorbidities. Subgroup analyses were performed according to age, sex, renal function, and history of cancer. A total of 222,977 individuals were included in this study. Among them, 92,230, 48,335, and 82,412 individuals underwent non-enhanced, linear GBCA-enhanced, and macrocyclic GBCA-enhanced MRI, respectively. Exposure to linear GBCAs slightly increased the risk of all-cause parkinsonism (adjusted HR, 1.13 [97.5% confidence interval, 1.08-1.19]), while exposure to macrocyclic GBCAs did not increase the risk (adjusted HR, 1.00 [97.5% confidence interval, 0.95-1.05]). The results were similar for all-cause parkinsonism requiring medication, PD, and secondary parkinsonism, whereas no significant association was observed for atypical parkinsonism. Exposure to linear GBCAs may slightly increase the risk of parkinsonism in adults, whereas exposure to macrocyclic GBCAs may not. Caution should be exercised when using linear GBCAs until further evidence emerges.
To evaluate the performance of the left atrial time-to-peak (TTP) derived from time-resolved magnetic resonance angiography (TR-MRA) as a noninvasive indicator of left atrial pressure (LAP) in patients with atrial fibrillation (AF). This retrospective study included 92 patients who underwent cardiac TR-MRA and catheter-based LAP measurements prior to catheter ablation for AF between January 2021 and December 2022. TR-MRA-derived TTP was measured in the left atrium using contrast-enhanced time-signal intensity curves. Catheter-based LAP measured during sinus rhythm served as the reference standard, with high LAP defined as ≥15 mmHg. Univariable and multivariable linear regression analyses were performed, with LAP as the dependent variable and echocardiographic parameters as covariates. The diagnostic performance of TTP for high LAP was evaluated using receiver operating characteristic (ROC) curve analysis. Among the 92 patients (mean age ± standard deviation, 60 ± 10 years; 70 male), 70 (76.0%) had low LAP, and 22 (23.9%) had high LAP. Mean TTP was significantly longer in patients with high LAP than in those with low LAP (25.1 ± 6.9 s vs. 16.9 ± 5.7 s, P < 0.001). In multivariable linear regression analysis, TTP remained independently associated with LAP (β = 0.46, P < 0.001). ROC analysis demonstrated good discriminative performance of TTP for identifying high LAP, with an area under the curve of 0.834 (95% confidence interval, 0.742-0.904). Using a TTP cutoff of >19.6 seconds, the sensitivity and specificity for identifying elevated LAP levels were 81.8% (18/22) and 75.7% (53/70), respectively. TR-MRA-derived TTP showed a significant independent association with invasively measured LAP. It may serve as a reliable noninvasive imaging marker for identifying high LAP in patients with AF undergoing catheter ablation.
To evaluate the diagnostic performance of magnetic resonance spectroscopy (MRS) in discriminating fumarate hydratase-deficient (FH-d) uterine leiomyomas (ULs) from FH-preserved ULs. This study consisted of three stages, with independent cohorts recruited for each stage: 1) sample-size estimation was retrospectively performed on UL specimens (diameter ≥3 cm; age, 20-40 years) from our database with immunohistochemistry (IHC) for 2-succinocysteine (2-SC) as the reference, without genetic testing, 2) MRS sequence optimization in confirmed FH germline mutation participants with ultrasound-detected ULs (diameter ≥3 cm), without IHC analysis, and 3) prospective diagnostic test accuracy was evaluated in consecutive participants with ultrasound-detected ULs (diameter ≥3 cm; age, 20-40 years), using IHC for 2-SC for determining the FH status and subsequent genetic testing in those with positive 2-SC results to identify whether FH mutations were germline or somatic in origin. The choline and fumarate peaks in MRS were classified as positive, negative, or technical failure (TF). TFs were analyzed separately and excluded from the primary diagnostic accuracy calculations. T1-, T2-, and diffusion-weighted images were interpreted as hyperintense or hypointense. The enhancement rate and apparent diffusion coefficient were also acquired. Diagnostic performance was compared between MRS and various magnetic resonance imaging (MRI) features. The optimal MRS parameters for the fumarate peak were echo time (TE) = 140 ms and an average of 256. Among the 360 prospective participants, 37 were confirmed to have FH-dULs. MRS showed positive fumarate peaks in 35 of 37 FH-dULs. After excluding six TFs, the positive fumarate peak on MRS showed 94.6% (35/37) sensitivity, 99.7% (316/317) specificity, and 99.2% (351/354) accuracy, all of which were significantly superior to those of other MRI features (P ≤ 0.002). A positive fumarate peak on MRS may be a useful imaging biomarker for diagnosing FH-dULs.
This corrects the article on p. 214 in vol. 27, PMID: 41735814.
暂无摘要（点击查看详情）